Funding Round For Cambridge Biotech Company Completed
News Nov 14, 2005
Activotec has announced that it has just completed a significant funding round to enable it to accelerate the growth of the company.
The money was raised quickly through a syndicate mainly composed of private high net worth investors, was significantly oversubscribed and had to be scaled back.
Activotec chief executive, Chris Littlewood, commented, "The funds will be invested in further research and development while expanding our current business."
"This will assist us in our dual strategy of creating and licensing technology to drug developers while also quickly growing our custom peptide and synthesiser sales."
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018